;
Atenolol Tablets

Atenolol Tablets

Product Details:

  • Grade Medicine
  • Formulations Type External Use Drugs
  • Formulations Form Tablets
  • Gender/Age Group Infants, Children, Adult, Women, Suitable For All Ages
  • Dosage Guidelines 50 mg
  • Storage Instructions Dry Place
  • Supply Ability : 2000 Box Per Day
  • Click to view more
X

Price And Quantity

  • 10 Box
  • 25 INR

Product Specifications

  • Dry Place
  • Tablets
  • External Use Drugs
  • 50 mg
  • Medicine
  • Infants, Children, Adult, Women, Suitable For All Ages

Trade Information

  • Cash Advance (CA), Cash in Advance (CID), Cheque, Letter of Credit (L/C)
  • 2000 Box Per Day
  • 5 Days
  • Yes
  • Free samples are available
  • Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
  • All India

Product Description

We are engaged in manufacturing, exporting and supplying highly effective Atenolol Tablets. Under experts' guidance, these tablets are precisely processed using excellent quality chemical substances and modern processing technique in sync with set industry standards. Offered tablets are 1 receptor antagonist that helps in treating hypertension, cardiovascular diseases, high blood pressure and angina and other related diseases. Further, we provide these Atenolol Tablets in diverse packaging at industry leading prices to the clients.

Features:

  • Effectiveness

  • Precise composition

  • Safe to use

  • Long shelf life

Additional Information

Atenolol (trade name Tenormin) can be used to treat cardiovascular diseases and conditions such as hypertension, coronary heart disease, arrhythmias, angina (chest pain) and to treat and reduce the risk of heart complications following myocardial infarction (heart attack)

Due to its hydrophilic properties, the drug is less suitable in migraine prophylaxis compared to propranolol, because for this indication, atenolol would have to reach the brain in high concentrations, which is not the case (see below).

Atorvastatin is a member of the drug class known as statins, used for lowering cholesterol. Atorvastatin inhibits the rate-determining enzyme located in hepatic tissue that produces mevalonate, a small molecule used in the synthesis of cholesterol and other mevalonate derivatives. This lowers the amount of cholesterol produced which in turn lowers the total amount of LDL cholesterol.

Pharmacology

As with other statins, atorvastatin is a competitive inhibitor of HMG-CoA reeducate. Unlike most others, however, it is a completely synthetic compound. HMG-CoA reeducate catalyzes the reduction of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, which is the rate-limiting step in hepatic cholesterol biosynthesis. Inhibition of the enzyme decreases de novo cholesterol synthesis, increasing expression of low-density lipoprotein receptors (LDL receptors) on hepatocytes. This increases LDL uptake by the hepatocytes, decreasing the amount of LDL-cholesterol in the blood. Like other statins, atorvastatin also reduces blood levels of triglycerides and slightly increases levels of HDL-cholesterol.

Indications

Atorvastatin is indicated as an adjunct to diet for the treatment of dyslipidemia, specifically hypercholesterolaemia. It has also been used in the treatment of combined hyperlipidemia.

In 2005, the PROVE IT-TIMI 22 trial compared 40mg/day pravastatin with 80mg/day atorvastatin.[5] Taken directly from the results of the trial: "Standard treatment (statin) with a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (pravastatin 40 mg/day) resulted in a 22% reduction in LDL cholesterol levels at 30 days compared with a 51% reduction with intensive therapy (atorvastatin 80 mg/day). At 2 years, a relative risk reduction of 16% (95% confidence interval, 5%-26%; P = 0.005) in the primary end point rate (death, myocardial infarction, documented unstable angina requiring hospitalization, coronary revascularization, or stroke) was seen in patients receiving intensive statin treatment compared with standard statin therapy. The benefit of intensive treatment was apparent as early as 30 days and was consistent over time. The PROVE IT-TIMI 22 data indicate that patients recently hospitalized for an ACS benefit from early and continued lowering of LDL cholesterol to levels substantially below current guideline recommendations."

Other Products in 'Sigman : Derma, Gynec & Cardiac ' category



Corporate Office
636/5, Laxmi Industrial Estate,
Ranchhodpura Road, Near Bhadaj,
RAKANPUR, Taluka: Kalol, District Gandhinagar - 382721,
Gujarat, India
Website: www.dewcareconcept.com, www.dewcareexport.com

Get in touch with us
RFQ Request For Quotation
Get Quotes For Your Buying Requirement. Tell Suppliers What You Need.
I agree to abide by all the Terms and Conditions of tradeindia.com